Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neural Development, Male Fertility, and Oncology Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NELL2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NELL2 ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View NELL2 Products |
| Gene Delivery | NELL2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View NELL2 Products |
| Benchmark Ab | Anti-NELL2 Recombinant Antibody Recombinant positive control for binding and neutralization assays. |
View NELL2 Products |
| Validator | NELL2 siRNA Set For knockdown verification in functional cell-based assays. |
View NELL2 Products |
| Related Target A | ROS1 The orphan receptor tyrosine kinase activated by NELL2, critical for sperm maturation and oncogenic signaling. |
View ROS1 Products |
| Related Target B | NELL1 Close homolog of NELL2. Critical for counter-screening to ensure drug selectivity and avoid off-target toxicity. |
View NELL1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ensuring native-like post-translational modifications (PTMs) for receptor binding | HEK293 mammalian expression host guarantees native glycosylation and correct disulfide bond formation of the multi-domain NELL2 protein. |
| Homolog cross-reactivity and off-target binding (NELL1 vs. NELL2) | High-purity NELL1 and NELL2 recombinant proteins available for stringent selectivity and counter-screening panels. |
| Lack of reliable positive controls for binding assays | Sequence-verified clinical-grade benchmark antibodies included in the catalog as reference standards. |
| High-background interference in cell-based assays | Endotoxin-controlled (<1.0 EU/ug) and sequence-verified reagents minimize non-specific cellular activation. |
Live NELL2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of NELL2 (Neural EGFL Like 2) is an emerging frontier spanning oncology, reproductive medicine, and neurology. As a secreted glycoprotein, NELL2 plays a pivotal role in axon guidance and neural survival, but recent breakthrough studies have highlighted its role as a key lumicrine factor regulating sperm maturation via its receptor, ROS1. This has opened up novel avenues for male contraceptive development and infertility treatments.
The race for NELL2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted small molecules and functional blocking antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific disruption of the NELL2-ROS1 signaling axis in both oncology (where ROS1 acts as an oncogene) and reproductive biology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic Institutes, Biopharma Startups | Neuropathic Pain, Glioblastoma | Neutralization assays requiring highly stable, bioactive-mimicking NELL2 recombinant proteins. |
| Small Molecules / Peptides | Reproductive Health Consortia | Male Contraception (NELL2-ROS1 disruption) | High-throughput screening (HTS) using binding assays with purified NELL2 and ROS1 extracellular domains. |
| Lentiviral Tools | Oncology Research Labs | Renal Cell Carcinoma, Prostate Cancer | Stable cell lines overexpressing NELL2 to study downstream signaling and phenotypic changes. |